Joint Clinical Trials Office
A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan Versus Investigator’s Choice of Chemotherapy in Patients who are not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic TNBC
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 14, 2024
Phase I Multicenter, Open-Label, First-in-Human Study of ORM-5029 in Subjects with HER2-Expressing Advanced Solid Tumors
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 14, 2024
A Randomized Double-Blind Placebo-Controlled Phase II Multi-Center Study of Inflammation Modification of Canakinumab to Prevent Leukemic Progression of Clonal Cytopenias of Unknown Significance (CCUS): IMPACT Study
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 14, 2024
A Two-tiered, Phase II, Rule-based, Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib (TEW-7197) for the Treatment of Anemic Patients with Philadelphia Chromosome-negative Myeloproliferative Neoplasms
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 14, 2024
A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal Onset Seizures
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 14, 2024
Do More, Feel Better: Lay-delivered Behavioral Activation in Senior Centers
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 17, 2024
Whole-Body Hyperthermia for Mood and Anxiety Disorders
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 24, 2024
A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 study Intended to Determine the Effects of seladelpar on normalization of Alkaline phosphatase Levels in Subjects with Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intoler
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 31, 2024
Multicenter randomized phase II trial of neoadjuvant radioimmunotherapy versus chemoimmunotherapy in patients with clinical stages IB-III (N2) non-small cell lung cancer
Study Status:
Open to Enrollment
Primary Investigator:
Date: June 4, 2024
A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination with BNT116 (FixVac Lung) versus Cemiplimab Monotherapy in First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with Tumors Expressing PD-L1 ≥50%
Study Status:
Open to Enrollment
Primary Investigator:
Date: June 17, 2024